# Diabetes Research Hub — Monitor Report

**Generated:** 2026-05-16 (automated scheduled run)
**Scan window:** since previous monitor report (2026-05-15)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`

---

## 1. File System Status

| File | Last Modified | Age | Status |
|---|---|---|---|
| `Analysis/Results/hub_monitor_report.md` | 2026-05-14 07:05 | 2d | OK |
| `Analysis/Results/clinical_trials_latest.json` | 2026-05-14 07:04 | 2d | OK (no fresh ingest) |
| `Analysis/Results/clinical_trials_snapshot_2026-05-14.json` | 2026-05-14 | 2d | OK (most recent daily snapshot) |
| `Analysis/Results/pubmed_recent_latest.json` | 2026-05-14 07:05 | 2d | OK (no fresh ingest) |
| `Analysis/Results/pubmed_recent_snapshot_2026-05-14.json` | 2026-05-14 | 2d | OK (most recent daily snapshot) |
| `Analysis/Results/literature_gap_report.md` | 2026-05-14 08:08 | 2d | OK |
| `Analysis/Results/literature_gap_data.json` | 2026-04-20 10:35 | **26d** | **STALE (>14d) — re-run recommended** |
| `Analysis/Results/agent_state.json` | 2026-05-15 08:14 | 1d | OK (refreshed yesterday) |
| `Analysis/Results/citation_validation.json` | 2026-05-14 08:09 | 2d | OK |
| `Research_Findings_Summary.md` | 2026-05-14 08:09 | 2d | OK |
| `Diabetes_Research_Tracker.xlsx` | 2026-04-17 14:50 | **29d** | **STALE — manual refresh due** |

### Notes on file status

The user's daily Python ingest scripts have **not been run on 2026-05-15 or 2026-05-16** — there are no `clinical_trials_snapshot_2026-05-15/16.json`, no `pubmed_recent_snapshot_2026-05-15/16.json`, and `hub_monitor_report.md` has not been regenerated since 2026-05-14 07:05. All "latest" feeds are therefore unchanged for a second day in a row, so the trial / PubMed deltas in this report restate yesterday's findings; only the web-search section reflects new information. Recommend running the daily scripts (see §6).

The most recent `hub_monitor_report.md` (2026-05-14) tracked **3 new files / 29 modified / 0 removed** vs. 2026-05-13 and flagged **563 result files older than 14 days**. Drift continues to widen with each missed daily run.

---

## 2. Clinical Trial Status

**Universe:** 793 tracked trials — T1D Cure & Cell Therapy 152 · T1D Immunotherapy & Prevention 72 · T2D Novel Therapies (Phase 2–3) 140 · Devices 221 · Recently Completed with Results 280.

**Status mix:** RECRUITING 266 · NOT_YET_RECRUITING 131 · ACTIVE_NOT_RECRUITING 110 · ENROLLING_BY_INVITATION 6 · COMPLETED 280.

**Phase mix:** PHASE3 122 · PHASE2 125 · PHASE2/3 16 · PHASE4 23 · PHASE1 13 · PHASE1/2 24 · EARLY_PHASE1 5 · NA/N/A 465.

### Δ vs. last monitor cycle (2026-05-15)

No new clinical-trial ingest has run since the 2026-05-14 snapshot, so the deltas captured 2026-05-14 vs. 2026-05-13 remain the most current trial-side news for a second day:

- **NCT05514535** (Novo Nordisk PHASE 3 — semaglutide + lower-dose insulin glargine in T2D) — **COMPLETED, results posted 2026-05-11**. Still the top item to triage into the tracker.
- **NCT04333823** (Adolescent T1D + SGLT2i, SickKids) — newly indexed Phase 3 / ACTIVE_NOT_RECRUITING.
- **NCT07379333** (HM11260C / efpeglenatide-class long-acting GLP-1, Hanmi) — status moved NOT_YET_RECRUITING → RECRUITING.
- **NCT05454891** (UCSF — extended bolus for meals in closed-loop AID) — results posted 2026-05-12.
- **NCT04226027 / NCT04286555** — newly indexed COMPLETED behavioral / dietary intervention trials (Columbia, Johns Hopkins).

### Phase 3 / Recruiting — Priority Watch List (unchanged from yesterday)

46 Phase 3 trials are currently recruiting across the corpus. Highest-priority watch entries:

| NCT ID | Sponsor | Therapy / Focus | Why It Matters |
|---|---|---|---|
| NCT04786262, NCT06832410 | Vertex | VX-880 / zimislecel (T1D islet cell) | Tier 3 cell therapy; NEJM/ADA evidence continues to build |
| NCT07088068 | Sanofi/Provention | Teplizumab Phase 3 (Stage 2 T1D) | Pairs with 2026-04-22 FDA pediatric expansion |
| NCT07222137, NCT07222332 | Eli Lilly | Baricitinib Phase 3 (delay Stage 3 T1D / preserve β-cell) | Active T1D immunotherapy line |
| NCT06962280, NCT06914895 | Eli Lilly | Tirzepatide T1D long-term / T2D | ACTIVE_NOT_RECRUITING — watch for primary completion |
| NCT06972472 | Eli Lilly | Orforglipron in obesity / overweight | Pairs with the orforglipron FDA approval |
| NCT07076199 | Novo Nordisk | Insulin icodec, weekly basal | Active T2D Phase 3 |
| NCT07379333 | Hanmi | HM11260C (efpeglenatide-class GLP-1) | Status flip to RECRUITING flagged this cycle |
| NCT07564414 | Novo Nordisk | CagriSema vs. oral semaglutide | NOT_YET_RECRUITING; watch for site activation |

### Recently posted results to triage (last 30 days)

- **2026-05-13** NCT04226027 (Columbia behavioral intervention) and NCT04286555 (Johns Hopkins DASH for diabetes) — newly closed.
- **2026-05-12** NCT05454891 (closed-loop AID extended-bolus) — relevant to Closed Loop AP domain.
- **2026-05-11** NCT05514535 (Novo Nordisk Phase 3, semaglutide + lower-dose glargine, T2D) — **highest priority**.
- **2026-05-05** NCT03734107, NCT04066959, NCT03859401 — behavioral / exercise / transition trials.
- **2026-05-04** NCT03940209 (Addressing basic needs to improve diabetes outcomes, Medicaid) — Phase 2, equity-relevant.
- **2026-04-30** NCT05823948 (Novo Nordisk Phase 3 once-weekly insulin / flash glucose).
- **2026-04-27** NCT05649137 (Novo Nordisk Phase 3 semaglutide in excess weight).

### Key-organization snapshot

- **Vertex:** 3 trials tracked — 2× Phase 3 zimislecel (RECRUITING), 1× VX-264 PHASE 1/2 (ACTIVE_NOT_RECRUITING). No status changes or new results in the past 7 days.
- **Eli Lilly:** 27 trials. Watch list (8 entries above). No new results posted this week.
- **Novo Nordisk:** 26 trials, including 4 CagriSema-related entries (3 Phase 3, 1 Phase 2). Most recent posted result remains NCT05514535 (2026-05-11).
- **Sana Biotechnology:** 0 indexed diabetes trials (consistent with prior monitor cycles — Sana's published islet work has been preclinical / single-patient case study under separate INDs).

---

## 3. PubMed Highlights

**Snapshot:** 145 unique papers across 16 alert domains (30-day lookback, generated 2026-05-14). 40 of those 145 papers were new vs. the 2026-05-13 snapshot.

### Domain activity (last 30d, unchanged since 2026-05-14)

- **High volume:** Diabetes AI/ML 199 · Diabetes Biomarker 151 · T2D GLP-1 New 143 · Diabetes Microbiome 122 · T2D Remission 68 · Diabetes Health Equity 56 · Diabetes Multi-Omics 53.
- **Low volume (notable):** T1D Stem Cell 20 · T1D Immunotherapy 17 · Closed Loop AP 16 · Diabetes Epigenetics 7 · Drug Repurposing 6 · LADA 5 · GLP-1 Pharmacogenomics 1.

The persistent very-low LADA and GLP-1-pharmacogenomics signals continue to align with the standing literature-gap findings (§4).

### Cross-Domain Papers — Highest Priority (13 in the latest pull)

| PMID | Date | Title (truncated) | Domains |
|---|---|---|---|
| **42123550** | 2026-04-29 | Operon™ platform — cardiometabolic biomarker screening (T2D precision review) | Biomarker · Microbiome · **Multi-Omics** (3-way) |
| 42051156 | 2026-04-29 | BDA/ABCD Consensus — clinical use of teplizumab in Stage 2 T1D | T1D Immunotherapy · Key therapy: **teplizumab** |
| **42128231** | 2026-05-12 | GLP-1RA-like effects of Bafetinib (in vitro + in vivo) | T2D GLP-1 · **Drug Repurposing** |
| 42104727 | 2026-05-09 | Stem-cell therapies for T1D — differentiation, translation, immune protection | T1D Stem Cell · Gene Therapy |
| 42108331 | 2026-05-11 | Automated insulin delivery in advanced CKD (Diabetologia) | T2D Remission · Closed Loop AP |
| 42089665 | 2026-05-06 | VEGFA-targeted ionizable LNPs for diabetic retinopathy | Gene Therapy · Complications |
| 42099240 | 2026-Jul | NLRP3 inflammasome mechanisms in diabetic nephropathy | Gene Therapy · Complications |
| 42129562 | 2026-05-13 | Sleep chart of biological ageing clocks (Nature) | AI/ML · Multi-Omics |
| 42125665 | 2026 | Biomarkers in diabetic neuropathy (MR + bioinformatics) | AI/ML · Biomarker |
| 42125497 | 2026 | Periodontal disease and pancreatic cancer | Biomarker · Microbiome |
| 42123756 | 2026-04-23 | Transcriptomics + ML + MR for diagnostic biomarkers | AI/ML · Biomarker |
| 42121908 | 2026-04-29 | AMPK networks for male reproductive health | Biomarker · Drug Repurposing |
| 42046753 | 2026 | Active breaks → glucose mgmt in T1D | T1D Immunotherapy · Closed Loop AP |

### Key Therapy Mentions (30-day window, abstract-level)

| Therapy | Papers (30d) | Notable |
|---|---|---|
| **dapagliflozin** | 27 (5 unique in latest pull) | Cardiorenal mechanism and outcome papers continue to dominate |
| **orforglipron** | 6 (5 unique) | PMID 42120723 (Phase 3b ATTAIN-MAINTAIN, *Nature Medicine*, 2026-05-13); PMID 42116665 (GI safety meta-analysis) |
| **icodec** | 4 (3 unique) | PMID 42119975 (T1D+T2D pooled safety, ONWARDS 1–6) |
| **teplizumab** | 3 (3 unique) | PMID 42051156 (BDA Consensus); 41796109 & 41535597 (real-world adult data) |
| **retatrutide** | 2 (2 unique) | PMID 42108533 (CKM review of triple-agonism). New TRIUMPH-4 Lilly readout this week — see §5 — not yet PubMed-indexed |
| **baricitinib** | 2 (2 unique) | Non-diabetes case reports |
| **zimislecel** | 0 | Still no PubMed indexing — Vertex output flows through NEJM/ADA/press; capture manually |
| **CagriSema** | 0 | No 30-day PubMed activity |

---

## 4. Gap Analysis Summary

The gap **report markdown** is current (regenerated 2026-05-14), but the underlying **`literature_gap_data.json` is now 26 days old (last refresh 2026-04-20)** and should be re-run.

### Top 5 Ranked Gaps (Bronze validation level)

1. **Beta Cell Regen × Health Equity** — gap 100, 0 joint pubs.
2. **Insulin Resistance × Islet Transplant** — gap 100, 1 joint pub.
3. **Islet Transplant × Drug Repurposing** — gap 100, 0 joint pubs.
4. **Islet Transplant × Health Equity** — gap 100, 0 joint pubs.
5. **Gene Therapy × LADA** — gap 100, 0 joint pubs.

(The Treg/CAR-T × Neuropathy and Glucokinase × Drug Repurposing pairs tie for #6; Islet Transplant × GWAS/Polygenic is deprioritized as methodologically distinct.)

### Alignment with Tier 1 Doctrine Areas

- **Drug Repurposing × Islet / × LADA** sits inside Tier 1 #4 (Drug Repurposing Computational Screening). PMID 42128231 (Bafetinib → GLP-1RA-like activity) remains the second concrete repurposing signal in two weeks; PMID 42121908 (AMPK / drug repurposing) is a third adjacent signal.
- **Health Equity × Beta Cell Regen / Islet Transplant / Treg-CAR-T** spans Tier 1 #6 (Epidemiology). Access-equity analysis of advanced cell / immune therapies remains a wide-open lane.
- **Islet Transplant × Insulin Resistance** intersects Tier 1 #1 (Multi-Omics Biomarker Integration) if framed via post-transplant metabolic phenotyping.

---

## 5. Breaking News (Web Verified, Last 7 Days)

Genuinely new since the 2026-05-15 monitor cycle:

- **NEW (week of 2026-05-11) — Boehringer Ingelheim SYNCHRONIZE-1 Phase 3 (survodutide).** Dual GLP-1 / glucagon agonist met co-primary endpoints in adults with obesity: **sustained weight loss up to 16.6%** at 76 weeks vs. **3.2%** placebo. First positive Phase 3 readout for a dual GLP-1/GCG agonist in chronic weight management; complements the Lilly retatrutide TRANSCEND-T2D-1 readout from last week and CagriSema. *(Silver — single sponsor source until peer-reviewed publication.)*
- **NEW — Eli Lilly retatrutide additional Phase 3 (TRIUMPH-4, obesity + osteoarthritis).** Updated investor release: **average weight loss ~71.2 lbs** plus substantial OA pain relief in the highest-dose arm. Strengthens the triple-agonist case beyond the TRANSCEND-T2D-1 metabolic data and extends the indication breadth (pain / mobility). *(Silver — investor release; full data reserved for ADA 2026.)*
- **NEW / upcoming — MannKind Afrezza pediatric expansion**, PDUFA date **2026-05-29**. If approved, first needle-free inhaled insulin option for pediatric T1D / T2D. Worth a tracker row pre-staging now. *(Silver — public PDUFA listing.)*
- **CONFIRMED — Ozempic oral pill (oral semaglutide) US availability** from 2026-05-04, off the May FDA action. Carries forward yesterday's note.
- **CONFIRMED — Langlara (insulin glargine-aldy)** interchangeable biosimilar to Lantus, FDA approved 2026-04-29. Cost / access implication for basal insulin remains relevant.
- **CONFIRMED — Awiqli (insulin icodec)** once-weekly basal insulin FDA approval (2026-03-26) continues to be reflected in ONWARDS-pooled safety papers.
- **CONFIRMED (still trending)** — Eli Lilly orforglipron / "Foundayo™" FDA approval, Sanofi Tzield (teplizumab) pediatric expansion, Vertex zimislecel NEJM/ADA 1-year readout (12/12 free of severe hypoglycemia, 10/12 insulin-independent).

Items deliberately skipped: routine country-level Ozempic launches, generic dapagliflozin approvals (already noted in prior cycles), individual case reports.

---

## 6. Recommended Actions

Prioritized for this cycle:

1. **Run the daily ingest scripts — two consecutive days have been missed.** Suggested order:
   - `python hub_monitor.py`
   - `python baseline_clinical_trials.py`
   - `python baseline_pubmed_alerts.py`
   Until these run, today's monitor cannot detect any 05-15 or 05-16 deltas in trials or PubMed.
2. **Add Boehringer Ingelheim SYNCHRONIZE-1 (survodutide) Phase 3** readout to `Research_Findings_Summary.md` and the GLP-1 / Dual-Agonist row of the tracker. Mark Silver pending peer-reviewed publication. *New since yesterday.*
3. **Add Lilly TRIUMPH-4 (retatrutide + OA, ~71.2 lb weight loss)** to the same tracker row alongside last week's TRANSCEND-T2D-1 entry. *New since yesterday.*
4. **Pre-stage the MannKind Afrezza pediatric PDUFA (2026-05-29)** as a watch item for the Devices / Pediatric T1D section of the tracker.
5. **Re-run gap analysis** — `python project1_literature_gap_analysis.py`. `literature_gap_data.json` is now 26 days old.
6. **Carry-forward — still pending from prior cycles:**
   - Add retatrutide TRANSCEND-T2D-1 topline (2026-05-14) to the GLP-1 / Multi-Agonist row.
   - Add OASIS 4 oral-semaglutide sub-analyses (ECO 2026, 2026-05-13) to the GLP-1 New section.
   - Update tracker with Novo Nordisk Phase 3 result NCT05514535 (semaglutide + low-dose glargine, results 2026-05-11).
   - Diabetes_Research_Tracker.xlsx is now 29 days old — schedule the manual sync that was queued two cycles ago.
7. **Re-review Drug Repurposing × Islet / × LADA** in light of PMID 42128231 (Bafetinib GLP-1RA-like effect) plus PMID 42121908 (AMPK / drug repurposing). Two repurposing-relevant cross-domain signals in two weeks. Tier 1 contribution area.
8. **Manually capture any Vertex zimislecel Phase 3 update** — still no PubMed indexing despite NEJM / ADA presence.

---

## 7. Evidence-Level Tags

Per the Research Doctrine, claims surfaced in this report carry the following levels:

- ClinicalTrials.gov / PubMed-indexed status changes: **Silver** (single authoritative source, public registry).
- New FDA approvals once cross-referenced with Drugs@FDA listing: **Gold** — **Silver** until verified this run.
- Phase 3 topline readouts from company press releases (retatrutide TRIUMPH-4, survodutide SYNCHRONIZE-1, OASIS 4): **Silver / awaiting peer-reviewed publication** — do not treat as Gold until full data are public.
- Cross-domain PubMed hits: **Bronze** until at least one independent replication is in hand.
- Gap-analysis rankings: **Bronze** (single bibliometric source).
- Preclinical / animal-only items (e.g., PMID 42128231 Bafetinib, PMID 42089665 VEGFA LNPs): **Bronze / preclinical**.

---

*Run produced autonomously by the diabetes-hub-monitor scheduled task. No source files were modified.*

## Sources

- [FDA Drug Approval Decisions Expected in May 2026 — Cardiology Advisor](https://www.thecardiologyadvisor.com/news/fda-drug-approval-decisions-expected-in-may-2026/)
- [FDA Approves First Generic Dapagliflozin Tablets — FDA](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-approves-first-generic-dapagliflozin-tablets)
- [FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss — AJMC](https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss)
- [Novo Nordisk's Ozempic oral pill US availability — PRNewswire](https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html)
- [Boehringer Ingelheim SYNCHRONIZE-1 Phase 3 (survodutide)](https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial)
- [Lilly retatrutide TRIUMPH-4 Phase 3 readout — Lilly investor](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average)
- [Lilly orforglipron Phase 3 — Lilly investor](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically)
- [Novo Nordisk Awiqli / icodec FDA approval — Yahoo Finance](https://finance.yahoo.com/sectors/healthcare/articles/novo-nordisks-awiqli-gets-fda-160800600.html)
- [ADA Standards of Care in Diabetes — 2026](https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2026)
